Quest Diagnostics

Quest Diagnostics

Haystack MRD™ by Quest Diagnostics is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery. Originally developed by Haystack Oncology, a Quest Diagnostics company, Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care.

Yes

Gastrointestinal (Colorectal) Cancer, Lung Cancer, Molecular Diagnostics, Personalized Medicine